New analysis method for predicting the risks and effects of immunotherapy

(Uppsala University) In a new study, researchers at Uppsala University have been able to show differences in how Rituximab, a monoclonal antibody drug, interacts with the blood of healthy individuals compared to patients with chronic lymphocytic leukaemia. This has awakened hopes that this analysis method could pave the way for important breakthroughs in immunotherapy research and treatment.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news